within Pharmacolibrary.Drugs.ATC.N;

model N06BA14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 0.325,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.199,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010666666666666666,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Solriamfetol is a dopamine and norepinephrine reuptake inhibitor used to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). It is approved by the FDA and EMA for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported from healthy adult volunteers following single oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06BA14;
